| Literature DB >> 34626214 |
Giulia Callegaro1, Steven J Kunnen1, Panuwat Trairatphisan2,3, Solène Grosdidier4, Marije Niemeijer1, Wouter den Hollander1, Emre Guney5, Janet Piñero Gonzalez5, Laura Furlong5, Yue W Webster6, Julio Saez-Rodriguez2, Jeffrey J Sutherland6, Jennifer Mollon3, James L Stevens7,8, Bob van de Water9.
Abstract
Mechanism-based risk assessment is urged to advance and fully permeate into current safety assessment practices, possibly at early phases of drug safety testing. Toxicogenomics is a promising source of mechanisms-revealing data, but interpretative analysis tools specific for the testing systems (e.g. hepatocytes) are lacking. In this study, we present the TXG-MAPr webtool (available at https://txg-mapr.eu/WGCNA_PHH/TGGATEs_PHH/ ), an R-Shiny-based implementation of weighted gene co-expression network analysis (WGCNA) obtained from the Primary Human Hepatocytes (PHH) TG-GATEs dataset. The 398 gene co-expression networks (modules) were annotated with functional information (pathway enrichment, transcription factor) to reveal their mechanistic interpretation. Several well-known stress response pathways were captured in the modules, were perturbed by specific stressors and showed preservation in rat systems (rat primary hepatocytes and rat in vivo liver), with the exception of DNA damage and oxidative stress responses. A subset of 87 well-annotated and preserved modules was used to evaluate mechanisms of toxicity of endoplasmic reticulum (ER) stress and oxidative stress inducers, including cyclosporine A, tunicamycin and acetaminophen. In addition, module responses can be calculated from external datasets obtained with different hepatocyte cells and platforms, including targeted RNA-seq data, therefore, imputing biological responses from a limited gene set. As another application, donors' sensitivity towards tunicamycin was investigated with the TXG-MAPr, identifying higher basal level of intrinsic immune response in donors with pre-existing liver pathology. In conclusion, we demonstrated that gene co-expression analysis coupled to an interactive visualization environment, the TXG-MAPr, is a promising approach to achieve mechanistic relevant, cross-species and cross-platform evaluation of toxicogenomic data.Entities:
Keywords: DILI; ER stress; Mechanism-based risk assessment; PHH; WGCNA
Mesh:
Substances:
Year: 2021 PMID: 34626214 PMCID: PMC8536636 DOI: 10.1007/s00204-021-03141-w
Source DB: PubMed Journal: Arch Toxicol ISSN: 0340-5761 Impact factor: 5.153
Overview of the properties of the modules associated with the stress response
| Module | HubGene | Nr genes | Key annotation | Preserved | Preservation statistics | Top5 TFs AC ( | Top3 GO terms (− log10 | Top3 Pathways (− log10 |
|---|---|---|---|---|---|---|---|---|
| PHH:15 | CTH | 91 | ATF4 | Yes | 5.0195,186,6.3597,143 | ATF4 (0); SSRP1 (9.79e-05); DDIT3 (0.00029) | Aminoacyl-tRNA ligase activity (4.88); ligase activity, forming carbon-oxygen bonds (4.88); ligase activity, forming aminoacyl-tRNA and related compounds (4.88) | Glycine Serine metabolism (7.47); Cytosolic tRNA aminoacylation (7.11); 3-Phosphoglycerate dehydrogenase deficiency (6.83) |
| PHH:295 | SESN2 | 6 | ATF4 | Yes | 1.4134,81,2.1443,48 | Amino acid transmembrane transport (5.94); antiporter activity (5.78); carboxylic acid transmembrane transport (5.71) | Amino acid/polyamine transporter I (8.05); Amino acid transport across the plasma membrane (6.86); Amino-acid transport (6.53) | |
| PHH:13 | PDIA6 | 121 | ATF6 | Yes | 17.3164,76,18.9546,65 | ATF6 (4.45e-08) | Endoplasmic reticulum part (41.9); endoplasmic reticulum (40.5); endoplasmic reticulum membrane (33.9) | Endoplasmic reticulum (50.1); Protein processing in endoplasmic reticulum— |
| PHH:59 | RRM2B | 21 | DDR | No | 0.6882,295,1.7648,196 | TP53 (3.05e-05); HEY2 (0.00458) | Intrinsic apoptotic signaling pathway by p53 class mediator (3.67); cytosolic part (3.03) | p53 signaling pathway— |
| PHH:83 | TIGAR | 16 | DDR | No | 1.0845,251,0.5865,326 | TP53 (2.58e-06) | Cellular response to UV (5.85); cellular response to DNA damage stimulus (5.73); cellular response to light stimulus (5.39) | Direct p53 effectors (10.3); Transcriptional Regulation by TP53 (5.87); Generic Transcription Pathway (5.28) |
| PHH:243 | GADD45A | 8 | DDR (GADD45 module) | Yes | 2.2642,62,2.1153,74 | Activation of MAPKKK activity (5.17); positive regulation of JNK cascade (4.48); positive regulation of p38MAPK cascade (4.43) | Growth arrest and DNA damage-inducible protein GADD45 (5.84); Ribosomal protein L7Ae/L30e/S12e/Gadd45 (4.94); 50S ribosomal protein L30e-like (4.7) | |
| PHH:62 | FKBP2 | 19 | ER stress | Yes | 6.0602,63,5.3855,109 | Endoplasmic reticulum part (7.87); endoplasmic reticulum (6.54); endoplasmic reticulum membrane (6.06) | Endoplasmic reticulum (5.29); Asparagine N-linked glycosylation (4.89); Protein processing in endoplasmic reticulum— | |
| PHH:131 | DNAJB1 | 11 | Heat shock | Yes | 5.6093,15,4.9477,12 | HSF1 (7.55e-15); NFE2L2 (0.00319) | Protein refolding (13.8); response to heat (13.1); response to temperature stimulus (12.2) | Attenuation phase (20.1); HSF1 activation (19.7); HSF1-dependent transactivation (19.2) |
| PHH:95 | DNAJA1 | 14 | Heat shock | Yes | 5.7558,37,3.3607,91 | HSF1 (7.04e-06); HSF2 (0.00457) | Response to unfolded protein (4.55); response to topologically incorrect protein (4.42); chaperone binding (4.11) | Cellular responses to stress (6.85); Chaperone (6.7); Cellular responses to external stimuli (6.38) |
| PHH:43 | NDUFA4L2 | 25 | Hypoxia | No | -0.1322,339,3.4149,181 | HIF1A (5.15e-07); EPAS1 (0.00133); CTCFL (0.00937) | Cellular response to hypoxia (9.08); cellular response to decreased oxygen levels (8.91); cellular response to oxygen levels (8.73) | Photodynamic therapy-induced HIF-1 survival signaling (8.85); HIF-1-alpha transcription factor network (7.49); BNIP3 (5.06) |
| PHH:22 | CXCL5 | 46 | Immune Response/NFkB | Yes | 6.3662,178,3.0489,261 | RELA (5.23e-12); REL (1.43e-09); NFKB1 (1.76e-09); JUN (4.22e-06); STAT3 (0.00145) | Extracellular space (15.6); response to cytokine (11.2); cytokine-mediated signaling pathway (10.7) | TNF signaling pathway— |
| PHH:136 | IRAK2 | 11 | Immune Response/NFkB | Yes | 3.7208,70,2.889,80 | RELA (0.00247) | I-kappaB kinase/NF-kappaB signaling (4.81); I-kappaB/NF-kappaB complex (4.78); T-helper 1 type immune response (3.78) | Alternative NF-kappaB pathway (5.3); NF-kappa-B/Dorsal (5.22); Rel homology domain, conserved site (5.22) |
| PHH:242 | IRF1 | 8 | Immune Response/NFkB | No | 1.9912,95,2.103,145 | RELB (2.22e-05); RELA (2.9e-05); NFKB1 (3.2e-05); REL (0.000182); STAT1 (0.00761) | Immune system development (4.89); negative regulation of immune system process (4.78); negative regulation of hemopoiesis (4.64) | cd40l signaling pathway (5.05); Interferon gamma signaling (4.9); NF-kappa B signaling pathway— |
| PHH:44 | CXCL1 | 24 | Immune Response/NFkB | No | 2.7193,202,0.7449,282 | RELA (2.67e-05); REL (3.08e-05); NFKB1 (0.000367); RELB (0.000737); FOXL2 (0.00161) | Chemokine activity (11); chemokine receptor binding (10.1); chemokine-mediated signaling pathway (10) | CXC chemokine (10.8); CXC chemokine, conserved site (10.8); CXC Chemokine domain (10.7) |
| PHH:70 | TIMP1 | 17 | Immune Response/NFkB | No | 0.9384,263,0.5635,309 | RELB (0.000257); RELA (0.00082); STAT1 (0.00155); NFKB1 (0.00971) | Carbohydrate binding (3.37); extracellular space (3.3); membrane-bounded vesicle (3.28) | Aminosugars metabolism (3.69); Fructose Mannose metabolism (3.33); Amino sugar and nucleotide sugar metabolism— |
| PHH:12 | IFI44L | 133 | Immune Response/STAT | Yes | 12.0082,120,8.5431,172 | IRF1 (0); STAT2 (0); IRF2 (1.59e-13); STAT1 (1.79e-10); IRF9 (0.00337) | Defense response to virus (36.7); response to virus (34.6); defense response to other organism (31.1) | Antiviral defense (38.3); Interferon Signaling (36.2); Immunity (28.8) |
| PHH:247 | PARP9 | 8 | Immune Response/STAT | Yes | 1.8303,60,2.498,38 | STAT2 (3.74e-11) | Innate immune response (4.93); negative regulation of viral life cycle (4.8); negative regulation of viral process (4.5) | Innate immunity (7.26); Antiviral defense (4.83); Cytokine Signaling in Immune system (4.3) |
| PHH:26 | PSMB8 | 38 | Immune Response/STAT | Yes | 3.5222,192,2.2305,285 | STAT2 (5.2e-09); IRF1 (2.14e-05); RFX5 (0.00621) | Defense response (7.36); antigen processing and presentation of peptide antigen via MHC class I (7.28); immune response (7.25) | Peptidase T1A, proteasome beta-subunit (6.13); antigen processing and presentation (5.66); Proteasome B-type subunit (5.65) |
| PHH:17 | RRAGD | 73 | Lysosome | Yes | 2.914,213,6.8888,155 | MITF (0.00554); USF1 (0.00966) | Vacuole (8.85); lytic vacuole (8.71); lysosome (8.71) | Lysosome (13.6); Lysosome— |
| PHH:2 | SLC2A2 | 743 | Mitochondrion | Yes | 10.001,235,13.9457,223 | Intrinsic component of membrane (5.26); integral component of membrane (4.99); single-organism cellular process (4.52) | Mitochondrion (7.89); Metabolism (7.34); Oxidoreductase (6.18) | |
| PHH:97 | STOML2 | 13 | Mitochondrion | Yes | 7.4364,19,4.0815,50 | Mitochondrial inner membrane (6.13); organelle inner membrane (5.83); mitochondrial membrane (5.21) | Mitochondrial translation termination (4.97); Mitochondrial translation elongation (4.97); Mitochondrial translation initiation (4.97) | |
| PHH:33 | MRPS33 | 30 | Mitochondrion | Yes | 3.8227,128,3.4387,166 | Organellar small ribosomal subunit (4.96); mitochondrial small ribosomal subunit (4.96); organellar ribosome (4.93) | Mitochondrion (7.24); Mitochondrial translation termination (5.33); Mitochondrial translation elongation (5.33) | |
| PHH:113 | CUEDC2 | 13 | Mitochondrion | Yes | 3.1314,100,2.9691,120 | Mitochondrial matrix (4.62); oxidoreductase activity, acting on NAD(P)H (4.43); mitochondrial part (4.13) | Mitochondrion (5.51); Transit peptide (4.77); The citric acid (TCA) cycle and respiratory electron transport (3.45) | |
| PHH:138 | MRPS2 | 11 | Mitochondrion | Yes | 3.6148,75,2.4957,90 | Mitochondrial translation (4.03); organellar small ribosomal subunit (3.84); mitochondrial small ribosomal subunit (3.84) | Mitochondrial translation termination (4.97); Mitochondrial translation elongation (4.97); Mitochondrial translation initiation (4.97) | |
| PHH:256 | NDUFA8 | 7 | Mitochondrion | Yes | 2.5157,34,1.2981,62 | Mitochondrial translation initiation (3.34); Mitochondrial translation (3.28); Translation (2.26) | ||
| PHH:173 | APEX1 | 10 | Mitochondrion | No | 2.0244,63,0.7689,263 | ATF1 (0.00434); USF1 (0.00551) | Mitochondrial respiratory chain (3.53); NADH dehydrogenase complex assembly (3.46); mitochondrial respiratory chain complex I assembly (3.46) | Mitochondrion (3.85); Mitochondrion inner membrane (3.46); Human Thyroid Stimulating Hormone (TSH) signaling pathway (3.15) |
| PHH:144 | TXNRD1 | 11 | NRF2 | No | 1.9258,155,1.5379,177 | NFE2L2 (7.32e-05); E2F6 (0.00294) | Oxidoreductase activity, acting on a sulfur group of donors (3.05) | NRF2 pathway (6.03); Nuclear Receptors Meta-Pathway (4.65); NADP-dependent oxidoreductase domain (4.36) |
| PHH:325 | CBR3 | 6 | NRF2 | No | -0.1565,345,0.488,276 | BACH1 (0.00127) | Nitric oxide biosynthetic process (3.53); nitric oxide metabolic process (3.45); reactive nitrogen species metabolic process (3.39) | Doxorubicin Metabolism Pathway (5.01); NADP (4.89); Doxorubicin Pathway, Pharmacokinetics (4.78) |
| PHH:337 | MEF2D | 6 | NRF2 (downstream) | Yes | 0.8942,104,2.2199,17 | NFE2L2 (0.000894) | RNA polymerase II transcription factor activity, sequence-specific DNA binding (3.62); sequence-specific DNA binding (3.03) | |
| PHH:76 | HNRNPDL | 17 | Proteasome | Yes | 4.3185,95,4.0359,112 | HOXC11 (0.0037) | Proteasome complex (4.31); endopeptidase complex (4.31); innate immune response-activating signal transduction (4.12) | Proteasome (4.99); Proteasome Degradation (4.5); Proteasome— |
| PHH:177 | PSMD6 | 10 | Proteasome | Yes | 9.1342,2,3.8193,28 | MYNN (0.00436) | Antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent (10.1); regulation of cellular amino acid metabolic process (9.87) | Proteasome— |
| PHH:82 | UNC119B | 16 | Proteasome | Yes | 2.3714,173,2.6321,188 | ELF2 (0.00175); PBX1 (0.00696) | Ubiquitin protein ligase binding (5.23); ubiquitin-like protein ligase binding (5.19); VCP-NPL4-UFD1 AAA ATPase complex (4.13) | Translesion Synthesis by POLH (3.87); DNA Repair (3.81); Ubl conjugation pathway (3.77) |
| PHH:4 | SIRT1 | 546 | Transcription regulation | Yes | 11.8721,161,20.488,126 | ZBTB11 (3.32e-05); ZNF639 (0.000161); ARID2 (0.000211); MIER1 (0.00329); ZNF644 (0.00614) | Nucleic acid-templated transcription (24.3); transcription, DNA-templated (24.2); RNA biosynthetic process (24) | Nucleus (34); Zinc-finger (30.9); Transcription (27.1) |
| PHH:134 | POR | 11 | Xenobiotic stress | No | 1.5875,132,0.3859,282 | SP3 (1e-04); SP1 (0.000854); HNF4A (0.00275); CEBPA (0.00381); THRB (0.00479) | Aromatase activity (8.97); oxidoreductase activity, acting on paired donors, [..], and incorporation of one atom of oxygen (8.62); xenobiotic metabolic process (8.4) | Cytochrome P450, E-class, group II (11.4); Cytochrome P450, E-class, CYP3A (11.4); Oxidation by Cytochrome P450 (9) |
| PHH:358 | CYP1A1 | 5 | Xenobiotic stress | No | 1.7944,26,0.365,189 | AHR (1.02e-06); USF1 (0.00127) | Toxin metabolic process (8.17); omega-hydroxylase P450 pathway (8.17); xenobiotic metabolic process (8.13) | Aryl Hydrocarbon Receptor Pathway (9.16); Xenobiotics metabolism (8.9); Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET) (8.81) |
Preservation statistics are, in order: Z summary PHHtoLIVER, MedianRank PHHtoLIVER; Zsum PHHtoRPH; MedianRank PHHtoRPH. More details can be found in Supplementary Tables S1–7
Fig. 3PHH stress modules interaction map. Cluster correlation matrix of the 87 modules correlating with well-annotated modules. On the left, modules are hierarchically clustered with Ward D2 algorithm using Pearson correlation (red–blue color scale) as distance. On the far left, the preservation status of each module is indicated with gray color scale (black—preserved, gray—not preserved). Clusters of modules with concordant annotation are highlighted with dashed squares. On the left, EGs (purple–orange color scale) for the exemplar compounds tunicamycin, cyclosporine A, Acetaminophen, Omeprazole are shown for the 87 modules, in dose– and time–responses. On the far right, modules names are shown together with their main annotation (available for the seed modules), in red highlighted the modules show in Table 1 (color figure online)
Fig. 5Upload of 50 donors PHH study S1500 + TempO-Seq set. a Histogram of modules coverage when uploading the targeted TempO-Seq gene set. Frequency (y axis) of modules percentage covered by the uploaded targeted gene set (x axis). b Percentage covered (y axis) for PHH modules, grouped on the x axis by whether they are part of the correlation matrix in Fig. 3 (blue) or not (green). The plot is divided into two sections, the first one showing modules where the hub gene was included in the uploaded gene set, the second one showing modules where the hub gene was not included in the uploaded gene set. c Mean correlation Eigengene for each module, whole genes set (x axis) versus after upload with the targeted TempO-Seq gene set (y axis). Points are colored based on whether they are part of the correlation matrix in Fig. 3 (blue) or not (green). d Pearson R correlation for each module between EGs calculated with the complete gene set, and EGs calculated with the S1500 + gene set, for all TG-GATEs experiments. Points are plotted against module coverage (x-axis) and are colored based on whether they are part of the correlation matrix in Fig. 3 (blue) or not (green). Inside: Pearson correlation calculated as previously grouped by whether they are part of the correlation matrix in Fig. 3 (blue) or not (green). Modules with coverage = 0% had been excluded. e Cluster correlation heatmap (complete clustering, Euclidean distance) showing the Pearson R correlation between modules EGs of the 50 donors dataset samples (10 µM, 24 h, pink color code on the left), TG-GATEs tunicamycin data obtained with the complete gene set (aquamarine color code on the left), and TG-GATEs tunicamycin data using only the S1500 + gene space (salmon color code on the left) (color figure online)
Fig. 1The PHH TXG-MAPr: an innovative tool to visualize and understand PHH toxicogenomic data. a Example gene expression data matrix. Log2FC values of genes (rows) are shown for multiple treatment conditions (columns). Four groups of co-expressed genes (modules PHH:13, 62, 118 and 144), highlighted with boxes and color, show consistent patterns across the experimental conditions and are exemplified with the gene networks on the right side. Treatments are clustered using Euclidean distance to group conditions that regulate the same groups of co-expressed genes. b Hierarchical tree view (dendrogram) of module scores at 24 h cyclosporine A exposure at HI dose level (6 µM). Highlighted modules are PHH:13, PHH:62 and PHH:118 which are strongly induced by CSA (orange/red circles), while module PHH:144 is unchanged (yellow circles). c Comparing modules and compounds. Top: gene log2 fold change (log2FC) for cyclosporine A (HI dose = 6 µM, 24 h) are plotted against gene log2FC for tunicamycin (MED dose = 2 µg/mL, 24 h), showing a Pearson correlation of 0.74. Center: module EGs for cyclosporine A are plotted against module EGs for tunicamycin, showing a Pearson correlation of 0.84. Bottom: EGs for module PHH:62 are plotted against EGs for module PHH:13 (all compounds, concentrations and time points) and show a Pearson correlation of 0.62. Straight blue line represents a fitted linear model. Gray shades represent confidence interval. d Grouping genes into modules. Top: gene network for module 62. Colors qualitatively represent log2FC upon treatment with cyclosporine A at HI dose (6 µM) for 24 h. Edges thickness is proportional to the adjacency value among the genes. The squared gene is the hub-genes. Center: module EGs profile for module PHH:62 at different cyclosporine A concentrations and time points (LO = 0.24 µM, MED = 1.2 µM, HI = 6 µM). Bottom: gene log2FC profile for hub-like genes belonging to module 62 at different cyclosporine A concentrations and time points. Color code of points and edges represents the correlation eigengene (corEG). e Annotating the modules. Top: Hierarchical tree view with module color and size proportional to the − log10 p value for the enrichment for the GO term “response to endoplasmic reticulum stress” (GO:0006520). Significantly enriched modules PHH:13, 15 and 62 with p values (< 0.01) are highlighted in blue. Center: Hierarchical tree view with module color and size proportional to the − log10 p value for the enrichment for the transcription factor ATF6. ATF6 enriched modules PHH:13 and 193 with significant p values (< 0.01) are highlighted in purple. Bottom: ATF6 activation score considering all its targets for cyclosporine A (LO = 0.24 µM, MED = 1.2 µM, HI = 6 µM) and tunicamycin (LO = 0.4 µg/mL, MED = 2 µg/mL, HI = 10 µg/mL) (color figure online)
Fig. 2Some PHH WGCNA modules are preserved in rat systems and connect to stress response pathways. a Z summary preservation score plot. Z summary preservation values of PHH modules in Rat in vivo Liver data (x-axis) are plotted against Z summary preservation values of PHH modules in Rat Primary Hepatocytes data (y-axis). Modules are colored based on their size (log10 transformed) and modules PHH:13 and PHH:62 are labeled. Higher scores imply better preservations. The dashed lines correspond to Z summary = 2 and Z summary = 10, above which a module can be considered, respectively, moderate and high preserved. b Median Rank preservation score plot. Median Rank preservation values of PHH modules in Rat in vivo Liver data (x-axis) are plotted against Median Rank preservation values of PHH modules in Rat Primary Hepatocytes data (y-axis). Modules are colored based on their size (log10 transformed) and modules PHH:13 and PHH:62 are labeled. Lower scores imply a higher rank and greater preservation. c Dose- and time-response EGs plots of modules representing stress response pathways. Modules are grouped by stress processes (roman letters) and their responses upon treatment with representative compounds is shown in dose–response (x axis), faceted by time. Modules are represented by different symbols, while compounds by different colors (color figure online)
Fig. 4Upload external data into the PHH TXG-MAPr. a Hierarchical tree view of module EGs upon 30 µM cyclosporine A exposure at 3 day (left), 5 day (middle) and 5 day + 3 day recovery (right). b Heatmap of all modules that have at least one condition with absolute EG score > 2 for cyclosporine A treatment. All concentrations and time points from TG-GATEs (0.24, 1.2 and 6 µM) and uploaded GEO: GSE83958 dataset (30 µM) are shown. Modules are clustered by Euclidean distance, Ward.D2 method. The purple color scale indicates to which cluster of Fig. 3 each module belongs, and gray color scale indicates the preservation status. c Zoom in for the third cluster obtained from the heatmap in B. Modules that have a strong annotation for ER stress (PHH:13 and PHH:62) or ISR (PHH:15) are in this module cluster and are strongly induced by 6–30 µM cyclosporine A. d Compound correlation plot comparing the module EG scores of the uploaded 30 µM CSA data at 5 day + 3 day recovery (y-axis), with CSA_24hr_6µM (x-axis) available in the PHH TXG-MAPr (Pearson R = 0.67). e Cluster correlation heatmap showing the Pearson R correlation between the conditions in TG-GATEs data (CSA, TUN, APAP) and the uploaded datasets with CSA and APAP exposures in PHH, HepG2 and HepaRG cells at various time points (see labels). Compounds cluster by mode-of-action, because ER stress inducers TUN and CSA are clustering together and show low correlation with the oxidative stress inducer APAP (color figure online)
Fig. 6Some PHH modules are associated with donor’s traits. a Dose–response plot of effect size and adjusted p value (log10 transformation, keeping the sign) resulting from the association of modules clusters to donors’ presence of liver pathologies. Modules clusters indicated by different color, number of donors showing (positive) and not showing (negative) the indicated trait are shown in the plot label. On the right, effect size and adjusted p value (log10 transformation, keeping the sign) of individual modules to trait associations most prominently contributing to the overall cluster associations highlighted with gray shadows. Modules are colored in different saturation level of the same hue of the cluster they belong to. b Boxplot of modules’ EGs negatively associated with liverpath, grouped by increasing concentrations and presence/absence of liver pathologies. **Adjusted p value < 0.01, *adjusted p value < 0.05 in logistic regression of individual modules. c Boxplot of normalized counts of genes belonging to module PHH:12 and significantly different between donors with or without liver pathologies with only DMSO treatment (Wilcoxon test, BH adj. p value < 0.05)